Charles A. Rowland, Jr., MBA , has served as a member of our Board since July 2017. Mr. Rowland s past board services include him being a member of the board of directors and chair of the audit committee of Generation Bio Co. from July 2018 through February 2026 and as a member of the board of directors and chair of the compensation committee of Nabriva Therapeutics, AG from January 2015 through January 2025. From June 2018 to January 2024, he served as a member of the board of directors and chair of the audit and compensation committees of Orchard Therapeutics plc, when Orchard Therapeutics plc was acquired by Kyowa Kirin Co., Ltd. From March 2015 to June 2022, Mr. Rowland served as a member of the board of directors and chair of the audit committee of Blueprint Medicines Corporation, and was a member of the board of Psioxus Therapeutics from August 2017 to October 2019, Vitae Pharmaceuticals, Inc. from September 2014 to September 2016, BIND Therapeutics, Inc. from May 2014 to July 2016, and Idenix Pharmaceuticals, Inc. from June 2013 to August 2014. From April 2016 to February 2017, he served as president and chief executive officer of Aurinia Pharmaceuticals Inc., and as a member of the board of directors of Aurinia from July 2014 to February 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated, an international biopharmaceutical company, from October 2008 until it was acquired by Shire plc in January 2014. Prior to joining ViroPharma, from 2006 to 2008, Mr. Rowland served as executive vice president and chief financial officer, as well as the interim co chief executive officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management. Mr. Rowland previously held positions of increasing responsibility at Biovail Pharmaceuticals, Inc., Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co., each a biopharmaceutical company. Mr. Rowland received a B.S. in Accounting from Saint Joseph s University and an M.B.A. with a finance concentration from Rutgers University. We believe that Mr. Rowland s financial and business expertise in the life sciences industry provide him with the qualifications and skills to serve as a member of our Board.